Automate Your Wheel Strategy on SGMO
With Tiblio's Option Bot, you can configure your own wheel strategy including SGMO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SGMO
- Rev/Share 0.318
- Book/Share 0.0763
- PB 7.5137
- Debt/Equity 1.1969
- CurrentRatio 1.0469
- ROIC -1.2556
- MktCap 172939599.0
- FreeCF/Share -0.1408
- PFCF -4.7787
- PE -2.3265
- Debt/Assets 0.2405
- DivYield 0
- ROE -2.9305
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SGMO | Truist | Hold | Buy | -- | $7 | Dec. 13, 2024 |
| Reiterated | SGMO | H.C. Wainwright | -- | Buy | -- | $10 | Dec. 10, 2024 |
News
What Makes Sangamo (SGMO) a New Buy Stock
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Sangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alexander D. Macrae - CEO, President & Director Gregory Davis - Head of Research & Technology Louise Wilkie - Head of Global Corporate Communications & Investor Relations Nathalie Dubois-Stringfellow - Senior VP & Chief Development Officer Prathyusha Duraibabu - Senior VP, CFO & Principal Accounting Officer Conference Call Participants James D Stamos - Jefferies LLC, Research Division Joshua Seth Fleishman - TD Cowen, Research Division Kuan-Hung Lin - Unidentified Company Liu Deng - Barclays Bank PLC, Research Division Luis Santos - Unidentified …
Read More
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 EARNINGS CALL.
Read More
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Positive
Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with phase 1/2 STAAR study data expected in 1H 2025, is a major near-term catalyst for investors to keep an eye on. Positive eGFR slope data could lead to an Accelerated Approval filing of isaralgagene civaparvovec for Fabry Disease in the 2nd half of 2025.
Read More
About Sangamo Therapeutics, Inc. (SGMO)
- IPO Date 2000-04-06
- Website https://www.sangamo.com
- Industry Biotechnology
- CEO Alexander D. Macrae Ch.B, M.B., MRCP,
- Employees 183